Collagenase-Functionalized Liposomes Overcome Stromal Barriers in Pancreatic Cancer
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Pancreatic ductal adenocarcinoma (PDAC) features a dense desmoplastic stroma dominated by type I collagen, which forms a physical barrier that limits vascular perfusion and drug penetration, resulting in poor therapeutic outcomes. Here, we report gemcitabine-loaded collagenase-conjugated liposomes (GLCLs) that enzymatically remodel the collagen-rich extracellular matrix (ECM) while delivering a cytotoxic payload. GLCL retained enzymatic activity and stability, exhibited prolonged circulation, and achieved superior tumor accumulation with deeper and more homogeneous intratumoral gemcitabine penetration than nonfunctionalized liposomes. In PDAC-bearing mice, GLCL showed a 6-fold higher tumor growth inhibition (69.8%) than gemcitabine-loaded liposomes without collagenase (GLL; 10.9%) at the same dose. Importantly, this work provides the first molecular-level validation of nanocarrier-mediated drug penetration in PDAC, achieved through a multiscale approach combining in vivo imaging, ex vivo fluorescence, and quantitative desorption electrospray ionization mass spectrometry imaging (DESI-MSI). GLCL enzymatically overcomes PDAC’s fibrotic collagen barrier, offering a clinically translatable strategy for deep intratumoral drug delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Cell Adhesion Molecules Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology
Seoul National University
Cancer Research Institute
Research Institute for Convergence Science
Department of Applied Bioengineering, Graduate School of Convergence Science and Technology
School of Transdisciplinary Innovations
Funding
Korea Health Industry Development Institute · National Research Foundation of Korea · Korea Evaluation Institute of Industrial Technology
References (100+)
Show source-provided references
1. World Cancer Research Fund International. Pancreatic Cancer Statistics ; 2025, https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/; (acccessed October 16, 2025).
2. 10.1097/JP9.000000000000020310.1097/JP9.0000000000000203 ↗
3. 10.1007/s12029-025-01183-210.1007/s12029-025-01183-2 ↗
4. 10.3390/cancers1508235410.3390/cancers15082354 ↗
5. 10.3322/caac.2187110.3322/caac.21871 ↗
6. 10.1038/s41392-020-00341-110.1038/s41392-020-00341-1 ↗
7. 10.1073/pnas.190862611610.1073/pnas.1908626116 ↗
8. 10.1038/s41419-022-05351-110.1038/s41419-022-05351-1 ↗
9. 10.3389/fonc.2021.75131110.3389/fonc.2021.751311 ↗
10. 10.1016/j.ccell.2021.02.00710.1016/j.ccell.2021.02.007 ↗
11. 10.1038/s41467-021-22490-910.1038/s41467-021-22490-9 ↗
12. 10.1038/s41598-019-50268-z10.1038/s41598-019-50268-z ↗
13. 10.1158/1078-0432.CCR-17-328410.1158/1078-0432.CCR-17-3284 ↗
14. 10.1038/s41598-017-10671-w10.1038/s41598-017-10671-w ↗
15. 10.1038/emm.2017.25510.1038/emm.2017.255 ↗
16. 10.1158/1078-0432.CCR-03-082510.1158/1078-0432.CCR-03-0825 ↗
17. 10.1097/00006676-199511000-0000710.1097/00006676-199511000-00007 ↗
18. 10.1158/1078-0432.CCR-14-105110.1158/1078-0432.CCR-14-1051 ↗
19. 10.1016/j.jconrel.2015.08.01710.1016/j.jconrel.2015.08.017 ↗
20. 10.2147/IJN.S50450310.2147/IJN.S504503 ↗
21. 10.1039/D5NR01067E10.1039/D5NR01067E ↗
22. 10.1038/nrm390410.1038/nrm3904 ↗
23. 10.3390/cancers1317444210.3390/cancers13174442 ↗
24. 10.1186/s12943-023-01744-810.1186/s12943-023-01744-8 ↗
25. 10.1038/jid.1982.1610.1038/jid.1982.16 ↗
26. 10.7150/thno.4744610.7150/thno.47446 ↗
27. 10.1021/acsnano.9b0239510.1021/acsnano.9b02395 ↗
28. 10.1186/s12951-022-01738-610.1186/s12951-022-01738-6 ↗
29. 10.1016/j.jconrel.2020.02.04010.1016/j.jconrel.2020.02.040 ↗
30. 10.1186/s12951-024-02968-610.1186/s12951-024-02968-6 ↗
31. 10.3390/s1609148810.3390/s16091488 ↗
32. 10.3390/ijms1604671810.3390/ijms16046718 ↗
33. 10.3389/fpls.2013.0041310.3389/fpls.2013.00413 ↗
34. 10.1021/acsomega.8b0301610.1021/acsomega.8b03016 ↗
35. 10.1016/j.cplett.2006.11.05010.1016/j.cplett.2006.11.050 ↗
36. 10.1002/2211-5463.1340610.1002/2211-5463.13406 ↗
37. 10.1021/jf030490p10.1021/jf030490p ↗
38. 10.1016/S0021-9258(18)45232-510.1016/S0021-9258(18)45232-5 ↗
39. 10.1021/bi00308a03710.1021/bi00308a037 ↗
40. 10.1016/j.ccell.2022.06.01110.1016/j.ccell.2022.06.011 ↗
41. 10.1016/j.ijpharm.2011.12.01510.1016/j.ijpharm.2011.12.015 ↗
42. 10.1158/0008-5472.CAN-03-147210.1158/0008-5472.CAN-03-1472 ↗
43. 10.1016/j.addr.2022.11461410.1016/j.addr.2022.114614 ↗
44. 10.1021/acs.molpharmaceut.8b0031910.1021/acs.molpharmaceut.8b00319 ↗
45. 10.1016/j.ccr.2012.01.00710.1016/j.ccr.2012.01.007 ↗
46. 10.5702/massspectrometry.A012910.5702/massspectrometry.A0129 ↗
47. 10.1021/acs.analchem.1c0457910.1021/acs.analchem.1c04579 ↗
48. 10.3390/metabo1303037710.3390/metabo13030377 ↗
49. 10.1002/mas.2173610.1002/mas.21736 ↗
50. 10.1016/j.trac.2021.11648210.1016/j.trac.2021.116482 ↗
51. 10.3390/molecules2104052210.3390/molecules21040522 ↗
52. 10.1200/JCO.1991.9.3.49110.1200/JCO.1991.9.3.491 ↗
53. 10.1200/JCO.1992.10.3.40610.1200/JCO.1992.10.3.406 ↗
54. 10.1111/bcp.1355710.1111/bcp.13557 ↗
55. 10.1078/0171-2985-0022310.1078/0171-2985-00223 ↗
56. 10.1186/s12935-024-03610-z10.1186/s12935-024-03610-z ↗
57. 10.3390/pharmaceutics1510244810.3390/pharmaceutics15102448 ↗
58. 10.7150/thno.1546410.7150/thno.15464 ↗
59. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
60. 10.1016/j.jconrel.2013.07.02610.1016/j.jconrel.2013.07.026 ↗
61. 10.1016/j.jconrel.2005.01.00810.1016/j.jconrel.2005.01.008 ↗
62. 10.1016/j.ijpharm.2007.11.00510.1016/j.ijpharm.2007.11.005 ↗
63. 10.1002/hep.2072010.1002/hep.20720 ↗
64. 10.1002/adma.20240994510.1002/adma.202409945 ↗
65. 10.3390/pharmaceutics1404072810.3390/pharmaceutics14040728 ↗
66. 10.3390/nano1410082310.3390/nano14100823 ↗
67. 10.1038/s41467-024-45254-710.1038/s41467-024-45254-7 ↗
68. 10.1248/bpb.b22-0038910.1248/bpb.b22-00389 ↗
69. 10.1016/j.biomaterials.2023.12218710.1016/j.biomaterials.2023.122187 ↗
70. 10.1002/smrj.5410.1002/smrj.54 ↗
71. 10.1007/s00345-019-02818-310.1007/s00345-019-02818-3 ↗
72. 10.1016/j.pep.2018.04.00110.1016/j.pep.2018.04.001 ↗
73. 10.3389/fimmu.2022.101617910.3389/fimmu.2022.1016179 ↗
74. 10.1016/j.drudis.2021.09.00410.1016/j.drudis.2021.09.004 ↗
75. 10.1016/j.jconrel.2024.02.02610.1016/j.jconrel.2024.02.026 ↗
76. 10.3390/pharmaceutics1705060610.3390/pharmaceutics17050606 ↗
77. 10.1016/j.jconrel.2021.03.01610.1016/j.jconrel.2021.03.016 ↗
78. 10.3389/fimmu.2022.80860610.3389/fimmu.2022.808606 ↗
79. 10.3390/ijms2217918110.3390/ijms22179181 ↗
80. 10.1073/pnas.151246511210.1073/pnas.1512465112 ↗
81. 10.1038/s41467-020-16838-w10.1038/s41467-020-16838-w ↗
82. 10.3389/fimmu.2021.71571910.3389/fimmu.2021.715719 ↗
83. 10.1021/acscentsci.0c0144810.1021/acscentsci.0c01448 ↗
84. 10.1158/0008-5472.CAN-21-248310.1158/0008-5472.CAN-21-2483 ↗
85. 10.1038/s43018-023-00536-910.1038/s43018-023-00536-9 ↗
86. 10.2147/IJN.S9383510.2147/IJN.S93835 ↗
87. 10.1186/s12885-023-10928-w10.1186/s12885-023-10928-w ↗
88. 10.7150/thno.2283410.7150/thno.22834 ↗
89. 10.1021/acs.molpharmaceut.5b0097110.1021/acs.molpharmaceut.5b00971 ↗
90. 10.1021/acsnano.5b0051010.1021/acsnano.5b00510 ↗
91. 10.2174/156720181366616041810570310.2174/1567201813666160418105703 ↗
92. 10.1038/s41467-024-48838-510.1038/s41467-024-48838-5 ↗
93. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
94. 10.1016/j.cotox.2020.01.00610.1016/j.cotox.2020.01.006 ↗
95. 10.1021/acscentsci.9b0113910.1021/acscentsci.9b01139 ↗
96. 10.1080/08982104.2024.238996910.1080/08982104.2024.2389969 ↗
97. 10.18632/oncotarget.2016210.18632/oncotarget.20162 ↗
98. 10.1080/08982104.2017.134383610.1080/08982104.2017.1343836 ↗
99. 10.1016/j.jconrel.2009.05.03610.1016/j.jconrel.2009.05.036 ↗
100. 10.1021/acs.molpharmaceut.8b0128410.1021/acs.molpharmaceut.8b01284 ↗